Neuro-modulation in HF, private equity owned ...
FDA approves PFA, breakthrough in PAH, residu...
Three aspects of the recent AF guideline docu...
More from AHA including SGLT2 inhibitors, blo...
An AHA Recap: SELECT, ORBITA2, and ARTESIA ar...
Renal denervation, a potential deadly decisio...
Tricuspid regurgitation therapy, two more lef...
More on the Million Hearts RCT, ENRICH AF, TA...
Listener feedback, oral anticoagulation in pa...
Three stories regarding GLP-1 agonists, imagi...